Indian Pharma Stocks Plunge as Trump Threatens "Major Tariffs"

Indian pharmaceutical stocks experienced a sharp sell-off on April 9th, triggered by remarks from Donald Trump indicating imminent "major tariffs" on pharmaceutical imports into the United States.

ma , sink 5% Trump, speaking at a National Republican Congressional Committee event, emphasized his intention to reshore drug manufacturing to the U.S., away from countries like China and others. He stated, "We're going to be doing something very big on drug imports — a major tariff is coming. We want these companies to make their products here, in America, not in China or elsewhere." While Trump did not provide specific details on the scope or timeline of these potential tariffs, the announcement sent ripples through the Indian pharma sector. The threat of substantial tariffs has raised concerns among Indian drug manufacturers who heavily rely on generic drug exports to the U.S. markets. Stocks like Gland Pharma and Lupin witnessed significant declines, sinking as much as 5%. Analysts at CLSA noted that while tariffs could impact Indian companies, they are likely to pass on the increased costs, given their strong market position in the U.S. The market is now watching closely for further clarification on the specifics of Trump’s proposed policies.